Intelliseq offers a sophisticated cloud-based platform designed for the automated analysis and clinical interpretation of Next Generation Sequencing (NGS) data. Their flagship product, the iFlow platform, enables users to seamlessly process raw genetic data, transforming it into actionable clinical insights without requiring specialized bioinformatics skills. The platform supports a variety of genomic analyses through its GeneSpect™ Reporters, which cater to different medical needs, including hereditary diseases, somatic mutations, and pharmacogenomics. This comprehensive approach allows for simultaneous processing of thousands of analyses, ensuring efficiency and scalability in genomic medicine.

The technology emphasizes safety and compliance, adhering to industry regulations such as ISO13485, HIPAA, and GDPR, which underscores its commitment to quality and data protection. Intelliseq's solutions are designed to be user-friendly, allowing healthcare professionals to customize workflows for diagnosis, therapy, and prevention. The platform also features advanced capabilities for manual variant filtering and classification, enabling users to leverage their expertise in the interpretation of genetic variants. Overall, Intelliseq's innovative tools and automated pipelines facilitate rapid and accurate genomic analysis, significantly enhancing the capabilities of clinical laboratories and research institutions.

United States

Intelliseq provides state of the art solutions for next generation sequencing. A team of passionate and skilled bioinformaticians, geneticists and molecular biologists approaches next generation DNA sequencing challenges with creativity and flexibility.

Intelliseq

Company Details